ASCO: Recent Drop in Additional Surgery Post Lumpectomy

Share this content:
ASCO: Recent Drop in Additional Surgery Post Lumpectomy
ASCO: Recent Drop in Additional Surgery Post Lumpectomy

TUESDAY, June 6, 2017 (HealthDay News) -- From 2013 to 2015 there was a decrease in additional surgery after initial lumpectomy, concomitant with a 2014 consensus statement endorsing a margin of "no ink on tumor," according to a study published online June 5 in JAMA Oncology. The research was published to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 2 to 6 in Chicago.

Monica Morrow, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues conducted a population-based cohort survey study involving 3,729 eligible women aged 20 to 79 years with stage I and II breast cancer diagnosed in 2013 to 2015. Responses from 342 surgeons' surveys regarding lumpectomy margins were also assessed.

The researchers found that from 2013 to 2015 there was a 13 percent increase in the rate of final lumpectomy, which was accompanied by a decrease in unilateral and bilateral mastectomy (P = 0.002). There was a 16 percent decrease in surgery after initial lumpectomy (P < 0.001). Overall, 69 and 63 percent of the responding surgeons endorsed a margin of no ink on tumor to avoid re-excision for estrogen receptor-positive, progesterone receptor-positive cancer and for estrogen receptor-negative, progesterone receptor-negative cancer, respectively.

"These findings suggest that surgeon-led initiatives to address potential overtreatment can reduce the burden of surgical management in patients with cancer," the authors write.

Abstract/Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths